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Abstract
Background: The AMBER (Assessment, Management, Best Practice, Engagement, Recovery Uncertain) care bundle
is a complex intervention used in UK hospitals to support patients with uncertain recovery. However, it has yet to
be evaluated in a randomised controlled trial (RCT) to identify potential benefits or harms. The aim of this trial was
to investigate the feasibility of a cluster RCT of the AMBER care bundle.
Methods: This is a prospective mixed-methods feasibility cluster RCT. Quantitative data collected from patients (or
proxies if patients lack capacity) were used (i) to examine recruitment, retention and follow-up rates; (ii) to test data
collection tools for the trial and determine their optimum timing; (iii) to test methods to identify the use of
financial resources; and (iv) to explore the acceptability of study procedures for health professionals and patients.
Descriptive statistical analyses and thematic analysis used the framework approach.
Results: In total, 894 patients were screened, of whom 220 were eligible and 19 of those eligible (8.6%) declined to
participate. Recruitment to the control arm was challenging. Of the 728 patients screened for that arm, 647 (88.9%)
were excluded. Overall, 65 patients were recruited (81.3% of the recruitment target of 80). Overall, many were
elderly (≥80 years, 46.2%, n = 30, mean = 77.8 years, standard deviation [SD] = 12.3 years). Over half (53.8%) had a
non-cancer diagnosis, with a mean of 2.3 co-morbidities; 24.6% patients (n = 16) died during their hospital stay and
35.4% (n = 23) within 100 days of discharge. In both trial arms, baseline IPOS subscale scores identified moderate
patient anxiety (control: mean 13.3, SD 4.8; intervention: mean 13.3, SD 5.1), and howRwe identified a good care
experience (control: mean 13.1, SD 2.5; intervention: mean 11.5, SD 2.1). Collecting quantitative service use and
quality of life data was feasible. No patient participants regarded study involvement negatively. Focus groups with
health professionals identified concerns regarding (i) the subjectivity of the intervention’s eligibility criteria, (ii) the
need to prognosticate to identify potential patients and (iii) consent procedures and the length of the
questionnaire.
Conclusions: A full trial of the AMBER care bundle is technically feasible but impractical due to fundamental issues
in operationalising the intervention’s eligibility criteria, which prevents optimal recruitment. Since this complex
intervention continues to be used in clinical care and advocated in policy, alternative research approaches must be
considered and tested.
Trial registration: International Standard Randomised Controlled Trial Number (ISRCTN) Register, ISRCTN36040085.
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care bundle, complex intervention
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Background
Clinical uncertainty in hospital settings
Clinical uncertainty has been defined as the inability to de-
termine the meaning and significance of illness-related
events [1]. It occurs when health professionals are unable
to predict outcomes accurately due to insufficient informa-
tion. Evidence suggests that in the last 30 days of life, the
combination of deteriorating health and clinical uncertainty
is highly distressing for patients in hospital and their fam-
ilies [2, 3]. This is amplified when discussions about their
situation and preferences for care and location of death do
not occur. Most people (67–80%) want to be informed
about their poor prognosis [4]. Research, however, has
identified that discussions about prognosis rarely occur [5].
This increases the likelihood of hospital deaths and also
leads to poor care satisfaction, mistrust and loss of confi-
dence in health professionals [6–9] and may lead to com-
plaints [10]. Clinical uncertainty also impacts the clinicians’
confidence and their practice. Health professionals fre-
quently struggle with uncertainty, which can result in
overtreatment or over-investigation [11], lack of communi-
cation with patients about their future [12, 13], and
increased care costs [14].
The potential for better care and the AMBER care bundle
In recent years, complex interventions [15, 16] aimed at
improving the care of patients who may be approaching
the end of life have become more common [17, 18]. In
2010, the AMBER care bundle was developed to improve
care in the acute hospital setting for patients who are de-
teriorating, clinically unstable with limited reversibility,
and at risk of dying in the next 1 to 2 months [19]. This
was subsequently amended to be at risk of dying during
their current episode of care despite treatment. The algo-
rithmic intervention of the AMBER care bundle is
designed to encourage health professionals to work with
patients and families to develop and document a clear
medical plan, including consideration of anticipated out-
comes, cardiopulmonary resuscitation and escalation sta-
tus, while acknowledging the uncertainty. This plan is
revisited daily and encourages regular communication
with the patient and their family regarding treatment
plans, place of care and any other concerns. The bundle
was designed to work alongside active medical care when
uncertainty about the outcome remains.
A recent non-randomised comparative study of the
AMBER care bundle with standard care, conducted in the
UK, identified mixed findings. In comparison to similar pa-
tients in the control group, the use of the AMBER care
bundle was associated with shorter lengths of hospital stay,
more frequent discussions about prognosis between health
professionals and patients, and higher awareness by
patients of their prognosis. The clarity of the information
provided, however, was rated lower by this group compared
to those in the control group [20]. Qualitative research
among health professionals has identified that the AMBER
care bundle was often used as a tool to label or categorise
patients, and indirectly served a symbolic purpose in affect-
ing the behaviour of individuals and teams. Participants de-
scribed the importance of the training associated with the
intervention but reported that adequate exposure to the
intervention, and the learning, varied [21].
Clinical equipoise, therefore, still exists in relation to the
AMBER care bundle. A robust comparative evaluation of
the intervention compared to standard care is, therefore,
needed. The UK Medical Research Council’s guidance on
the development and evaluation of complex interventions
[15] and the Methods of Researching End-of-life Care
(MORECare) statement [16] both recommend a feasibility
study before full evaluation. Feasibility studies, now more
common in palliative and end of life care [22], enable re-
searchers to identify problems that might undermine the
acceptability and delivery of the intervention or the conduct
of a fully powered trial [23, 24]. Researchers are then poten-
tially able to remedy problems with the intervention, trial
design, or conduct by returning to the development phase,
rather than proceeding to a full trial. This has important
implications for the efficient use of resources, ensuring they
are not directed to studies that produce a null result due to
an unfeasible study design [25]. Moreover, it is also uneth-
ical to run a full trial before running a feasibility study.
In this paper, we report on the feasibility of conduct-
ing a pragmatic multi-centre cluster randomised con-
trolled trial (RCT) of a hospital-based complex
intervention (the AMBER care bundle) that aims to bet-
ter serve patients whose situations are clinically uncer-
tain and where there is a risk that they will die during
their hospital stay, versus standard care. Four feasibility
objectives were specified:
1. To examine recruitment, retention, and follow-up
rates
2. To test data collection tools for the trial and
determine what would be their optimum timing in
a larger trial
3. To test methods for identifying the use of financial
resources
4. To explore the acceptability of study procedures for
patients and health professionals.
Methods
Design
This study was registered with the International Stand-
ard Randomised Controlled Trials registry (ISRCTN:
36040085). Favourable ethical opinions were obtained
from the national research ethics committee for Camden
and King’s Cross (16/LO/2010) and the Health Research
Authority. National Health Service (NHS) research
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governance approvals were obtained from each partici-
pating study hospital.
We conducted a parallel cluster RCT with a 1:1 alloca-
tion ratio, employing convergent mixed methods, with
the quantitative and qualitative data given equal import-
ance. Data were collected sequentially and analysed con-
currently. A cluster RCT design was chosen because the
implementation and delivery of the intervention were at
an organisational level, in this case, hospital wards, and
not the patients. Cluster RCTs are used to avoid
contamination between treatment groups [26, 27]. This
study comprised the trial, an examination of patients’
clinical records, and focus groups with health
professionals.
Study setting
The study took place across purposefully selected gen-
eral medical wards in four clusters, in this case, district
general hospitals (DGHs) in England. DGHs are major
secondary-care facilities that typically provide an array of
diagnostic and therapeutic services to the local popula-
tion. There are over 142 DGHs in the UK [28]. The four
DGHs selected serve diverse populations, including
those with ethnic diversity and material deprivation. The
hospitals have different strengths and weaknesses in
terms of their Care Quality Commission ratings [29].
Participant recruitment and implementation of the
AMBER care bundle were limited to one or two general
medical wards at each hospital site. Selection of study
wards at each site was informed by heat maps that pro-
vided contextual information at a ward level on the
number of deaths during and up to 100 days after admis-
sion. Additional data comprised the number of patients
who died with an individualised approach to the last
days of life care and the number of hospital readmissions
prior to a patient’s death. Wards with the highest num-
ber of deaths per year were considered to be suitable for
the study.
Randomisation and masking
Hospitals were randomly assigned to the intervention or
control arms at the level of the cluster via an independ-
ent clinical trials unit by randomly sequencing the order
of randomisation and then randomising the sites in this
order into fixed blocks of two. Research nurses collect-
ing data from patient participants were not masked to
the group allocation. Quantitative analyses were per-
formed, masked for the group allocation.
Patient participants and the recruitment process
Research nurses identified patients (or their proxies) in
the intervention and control wards daily who fulfilled
the eligibility criteria aligned with those of the AMBER
care bundle i.e. patients:
1. who were deteriorating, whose status was clinically
uncertain, and with limited reversibility
2. at risk of dying during their current episode of care,
despite treatment
3. able to provide written informed consent or where
a personal consultee could be identified and
approached to give an opinion on whether the
patient would have wished to participate in the
study.
Research nurses scanned the hospital ward white-
boards to identify potential patient participants, who
were then discussed with the clinicians to confirm their
suitability for the study. All participants were considered
to have mental capacity unless this was established
otherwise, and all practicable steps were taken to enable
individuals to decide for themselves whether they wished
to participate. Potential participants’ level of capacity
was discussed with referring clinicians to identify those
with possible impaired capacity and to anticipate the
likely consent procedure. Capacity was established in the
initial meeting with the patient using the Mental Cap-
acity Act (MCA) four-step process [30]. It was assessed
whether the individual can:
(i) understand the information given to them about
the study
(ii) retain the information (even for a short time)
(iii)use or evaluate that information
(iv) communicate their decision (by any means).
Recruitment of staff members to focus groups
Health professionals from study wards and the research
nurses were invited via posters to participate in one of
the four focus groups representing the study wards. Of
those who expressed interest, we attempted to recruit a
range of health professionals with different levels of ex-
perience. Written informed consent was obtained from
health professionals prior to the focus groups taking
place. Consent was obtained at the end of the focus
groups from any health professionals who joined late but
wished to participate.
Data collection
Patient (or proxy) questionnaires and outcome measures
After obtaining informed consent or, for adults lacking
capacity, permission from a proxy (A third party), re-
search nurses conducted baseline face-to-face interviews
with patient participants, or their proxies, on the study
wards. A questionnaire captured patient participant
demographic and clinical information. Health perform-
ance status was assessed using the Australia-modified
Karnofsky Performance Scale [31] and the following
measures.
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Patient and family anxiety and communication
The first of the two candidate primary outcome mea-
sures was the patient/family anxiety and communica-
tion subscale of the Integrated Palliative care
Outcome Scale (IPOS) [32, 33]. These data were col-
lected at baseline, 3–5 days, and 10–15 days. This
patient-centred outcome was chosen because of the
intended benefits of the AMBER care bundle and the
findings from a comparative observational study in
which psychosocial issues were identified as a central
concern to patients and their families [34]. The pa-
tient/family anxiety and communication subscale in-
cludes items on (i) being in receipt of information,
(ii) addressing practical matters, (iii) sharing feelings
with family, (iv) being at peace, (v) the patients’ level
of anxiety and depression, and (vi) family distress and
ability to share feelings.
Patient experience
The second candidate primary outcome measure was
howRwe [35], a patient-reported experience measure
that examines changes in patients’ reported experi-
ences of care. This was collected at baseline, 3–5 days,
and 10–15 days. The measure, used among patients
who possessed mental capacity, is succinct, compris-
ing just four items relating to the delivery and organ-
isation of care. howRwe has been used successfully
for hospital inpatients, hospital outpatients, and gen-
eral practice patients, and patients in care homes or
domiciliary care [36, 37].
Health-related quality of life and health resource utilisation
The EQ-5D-5L [38] was used to measure health-related
quality of life. It measures five health-related quality of
life dimensions: (i) mobility, (ii) self-care, (iii) usual ac-
tivities, (iv) pain and discomfort, and (v) anxiety and de-
pression, using two descriptive systems and a visual
analogue scale. These data were collected at baseline, 3–
5 days, and 10–15 days. Each dimension has five levels,
ranging from having ‘no problems’ to ‘being unable to
perform’. The visual analogue scale records the respon-
dent’s self-rated health on a vertical scale, where the
endpoints are labelled ‘best imaginable health state’ and
‘worst imaginable health state’. This information can be
used as a quantitative measure of health outcomes as
judged by individual respondents.
Data on health resource utilisation were collected
using the Client Service Receipt Inventory [39, 40].
These data were collected at baseline and 10–15 days.
This inventory measures the use of health, social, and in-
formal care in the 3 months prior to hospital admission,
and then during the inpatient stay for up to 10–15 days
(time point three).
Views on being involved in the study
Patient participants were asked to provide responses to
questions about being involved in the study on a five-
point scale ranging from 1 (highly positive) to 5 (highly
negative). These views were collected at baseline, 3–5
days, and 10–15 days. In addition, they were asked if
they would recommend or not recommend involvement
in the study to other patients. This included an option
for them to respond as ‘don’t know’ [41]. Free-text com-
ments were also invited.
Quantitative data analysis
The analysis followed the Consolidated Standards of
Reporting Trials (CONSORT) guidelines (Fig. 1) and
was conducted in collaboration with the clinical trials
unit. Two statisticians (WG and RW), the chief investi-
gator (JK), and the health economist (DY) were blind to
the randomisation. Data were entered into predesigned
Epidata databases [42]. In total 10% of the data were
double entered and cross-checks were conducted. No
discordance was detected for the candidate primary out-
come measures (100% match for the IPOS subscale and
howRwe) and very high accuracy for the rest of the
questionnaires.
Since this was a feasibility study, a formal power calcu-
lation was not appropriate. Based on the information
about the number of deaths and prior studies, we aimed
to recruit 40 patients per study arm to provide us with
sufficient data to test data collection forms and ques-
tionnaires, examine the appropriateness of candidate pri-
mary outcome measures, determine what would be the
optimum data collection timing for a larger trial, and ex-
plore the acceptability of study procedures to patient
participants. Any investigations of changes in study pa-
rameters were exploratory only.
Descriptive statistics on demographic and study vari-
ables were calculated as means, medians, ranges, stand-
ard deviations (SDs), and percentages (for categorical
variables). No tests of significance were conducted.
However, 95% confidence intervals, rounded up to one
decimal place, were provided to indicate the precision of
the estimates from the feasibility trial. The analysis of
the IPOS data focused only on those participating pa-
tients with complete data for all IPOS patient and family
anxiety and communication subscale items.
Economic evaluation is an emergent area in palliative
care and ambiguity still surrounds best practice [39].
Procedures to inform the economic evaluation in the full
cluster RCT protocol were reported, focusing on re-
source implications from health and social care, and so-
cietal perspectives. We aimed to make preliminary cost-
effectiveness calculations (e.g. combining Client Service
Receipt Inventory data on costs and the EQ-5D-5L
score).
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Responses to the five items in EQ-5D-5L were used to
generate the index score for each patient. Theoretically,
the index score ranges from 0 (death) to 1 (full health).
Some EQ-5D-5L profiles were evaluated as below zero,
implying that the individual considers their current qual-
ity of life as worse than death.
Qualitative data
Focus groups
A topic guide was developed to explore health profes-
sionals’ views on the conduct of the feasibility cluster
RCT. The four focus groups were led by two senior re-
searchers (JK and CE), both of whom have experience in
palliative care research and qualitative research. Field
notes were taken by EY and HJ to provide a contextual
understanding of any non-verbal communication
expressed during the focus groups. All focus groups
were audio-recorded and lasted 50 mins in intervention
site 1, 49 mins in intervention site 2, 60 mins in control
site 1, and 65 mins in control site 2.
Qualitative data analysis
The qualitative data analysis was informed by the frame-
work approach, in which data are inductively coded and
organised to identify themes emerging from the focus
groups [43]. To address issues of rigour and trustworthi-
ness in the analysis, we (JK, EY, and HJ) independently
examined the focus group transcripts, met to develop a
thematic framework, and then independently coded the
transcripts. Where coding differed, these issues were
reconsidered by JK, EY, and HJ in detail until a consen-
sus was achieved [44]. To avoid making unwarranted
claims about patterns and regularities in the data, care
was taken to examine what appeared to be more unusual
or non-confirmatory views and we considered what the
data told us about their causes [44]. Excerpts from the
focus group transcripts are presented to illustrate
themes and represent a range of views, rather than being
reliant on selected individuals. All quotes from health
professionals have been anonymised to preserve
confidentiality.
Results
Recruitment, retention and follow-up rates
We had initially planned for recruitment to take place at
each of the study sites for 3 months, with an expected
average of seven participants being consented per
month. However, recruitment was much slower than ex-
pected. Consequently, recruitment was extended to 10
months (June 2017 to March 2018). During this time, a
total of 894 patients (130 in the intervention arm and
764 in the control arm) were screened for eligibility.
In the control arm, all patients on the study wards
were screened by research nurses for potential eligibility
Fig. 1 Consolidated Standards of Reporting Trial 2010 (CONSORT) flow diagram of study
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against the inclusion criteria, which corresponded with
the AMBER care bundle eligibility criteria. Patients,
however, were deemed as being eligible only after con-
firmation by the clinical team. Subsequently, a member
of the clinical team was required to explain to patients
(or their relatives) their situation of clinical uncertainty
and the purpose of the study. The most common reason
preventing research nurses from approaching potential
participants to ask for their informed consent was un-
completed clinical tasks, for example the failure to speak
with family members about a patient’s current clinical
situation. For the intervention arm, the identification of
potential patient participants for inclusion in the study
was guided by clinical decisions on whether patients
were suitable to be supported by the AMBER care bun-
dle. Since clinical teams assessed patients on the study
wards to be supported by the AMBER care bundle on
their daily handover meetings, the research nurses did
not repeat this process. Although a larger number of pa-
tients were assessed for eligibility in the control arm of
the study, the final number of patients who were eligible
(n = 117) is very similar to those who were eligible in the
intervention arm (n = 103).
Table 1 presents the number of patients screened and
successfully recruited at each of the study sites. Only
1.9% (n = 8) and 8.9% (n = 28) of those screened in the
control arm (both sites) were eventually recruited. The
screening log for control site 1 provided detailed infor-
mation on the characteristics of eligible and ineligible
patients, and those who consented or refused. The log
reported that of the patients screened who met the first
eligibility criterion (deteriorating, clinically uncertain,
and with limited reversibility), 55 (15.1%) did not meet
the second criterion (at risk of dying during their current
episode of care). Other sites provided only a limited
range of information concerning potential recruits and
control site 2 did not routinely keep a recruitment log.
Recruitment rates were higher at the intervention sites,
where 25.0% (n = 20) and 18.0% (n = 9) of those screened
were recruited, respectively.
Clinicians and research nurses at the control sites re-
ported challenges in identifying potential patients who
fulfilled the eligibility criteria, particularly regarding the
risk of dying during their current episode of care. Unlike
health professionals at the intervention sites, they were
not trained and guided in identifying these patients, as
providing this education and support may have resulted
in potential contamination of patient care. Since one of
our study objectives was to examine critically how the
study operated under field conditions, we reviewed pa-
tient recruitment in terms of the eligibility criteria over
4 months to assess the feasibility of recruitment. As a re-
sult, a pragmatic decision was made with the trial steer-
ing group to remove the ‘risk of dying’ criterion,
focusing instead on just the first AMBER care bundle
eligibility criterion, i.e. patients who are deteriorating
and patients whose situations are clinically uncertain,
with limited reversibility. A substantial protocol amend-
ment was obtained from the NHS research ethics com-
mittee, in addition to local research governance
permissions. We planned to monitor the effect of this
change on recruitment, but control site 1 did not have
the capacity to implement the revised recruitment strat-
egy by the time approvals had been obtained. Control
site 2 recruited eight more participants after this change.
Sample characteristics
Participants in both trial arms were predominantly white
British and widowed, and most were either living com-
fortably or coping with their present level of income.
The majority (64.6%, n = 42) of all 65 patient participants
lacked mental capacity and therefore, proxy assent was
required on their behalf. Control site 2, in an urban set-
ting, had a more ethnically diverse sample profile
Table 1 Summary of numbers screened, excluded and recruited, by site and study arm
Control site 1 Control site 2 Intervention site 1 Intervention site 2 Total
Screened 449 315 80 50 894
Not eligible 365 282 22 5 674
N (%) of those screened who were eligible 84 (18.7) 33 (10.4) 58 (72.5) 45 (90) 220 (24.6)
Reasons for non-recruitment
Lacked capacity and no caregiver 4 2 8 6 20
Too unwell 19 0 2 6 27
Died 0 0 7 5 12
Discharged or discharge planned 13 0 6 2 21
Declined 5 2 6 6 19
Clinical review/tasks 28 1 4 8 41
No reason provided 7 0 5 3 15
N and % of those eligible who were recruited 8 (9.5) 28 (84.8) 20 (34.4) 9 (20) 65 (29.5)
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compared to the other sites. There were differences be-
tween the trial arms (Table 2). In the control arm, most
patients were men aged between 65 and 79 years with a
cancer diagnosis, while in the intervention arm, the ma-
jority were women aged 80 years or older with a non-
cancer diagnosis. The older age and non-cancer diagno-
ses of the patients in the intervention arm are likely due
to the inclusion of two care-of-the-elderly wards at
intervention site 1.
Reasons for hospital admission
Reasons for the patient participants’ admission to
hospital included shortness of breath, falls, and confu-
sion. Out of 65 participants, 62 (95.4%) had an un-
planned admission to hospital through an emergency
department. They had a range of different illnesses
(Table 3), and an average of 2.3 comorbidities (range
1–4) (Table 4), the most common being those
associated with circulatory disorders.
Descriptive analyses of candidate primary outcome
measures
Table 5 presents the levels of missing data and an ex-
ploratory analysis of patient primary outcomes for the
IPOS subscale and the howRwe at each of the time
points (mean and SD). The mean IPOS subscale score at
the baseline was 13.3 (SD 4.8) in the control arm and
13.3 (SD 5.1) in the intervention arm, i.e. within the
moderate range. This remained fairly consistent across
the time points: 13.3 at 3–5 days (change of 0 from the
baseline) and 10.3 at 10–15 days (change of − 3.0 from
the baseline) in the control arm; 14.6 at 3–5 days
(change of + 1.3 from the baseline) and 13.9 at 10–15
days (change of + 0.6 from the baseline) in the interven-
tion arm. Although the howRwe scores changed across
time points, it is not possible to comment on whether
this is clinically significant because of the small sample
size and the high rate of attrition between time points.
Economic evaluation process
The descriptive statistics of service use showed that util-
isation was within plausible ranges. Patients interviewed
at 10 – 15 days, reported the use of investigations/tests
and the informal care provided, but no health service
use due to hospitalisation was reported between baseline
and follow-up. Deriving EQ-5D index score was feasible
for those who answered the questions on five dimen-
sions (Table 6). Furthermore, we determined it was feas-
ible to collect the data on health and social care service
use, informal care provision and quality of life at base-
line and at 10-15 days. Missing values in the data were
not problematic (less than 9.0%). We decided not to cal-
culate preliminary cost-effectiveness because attrition at
10-15 days reduced the number of paired samples avail-
able to twelve.
Patient participant views on being involved in the study
Patient participants considered their involvement in the
study positively. Only one participant, who was in the
control arm, did not want to complete the study ques-
tionnaire (no reason was stated). Some stated they were
happy to participate due to the positive interaction with
the research nurses, for example: ‘The research coordin-
ator is very polite and explained everything about the
study’ (Con2-014). Others were motivated by a sense of
altruism, believing involvement would help others and
improve services: ‘If you can help others, then it’s worth
doing’ (Int2-007). A number of participants also encour-
aged other patients to take part in the study, reiterating
that their involvement would ‘help others’.
Focus groups with health professionals
In total, we conducted four focus groups with health
professionals, one at each of the four study sites. Their
views focused on the following issues: (i) the eligibility
criteria for the AMBER care bundle and its implications
for patient eligibility in the study, (ii) considerations of
study settings and processes, and (iii) the impact of the
feasibility study on research nurses. Details of the partic-
ipants in the four focus groups at each of the study sites
are presented in Table 7. Themes and illustrative quotes
are presented in Table 8.
Eligibility criteria and issues with prognostication
Participants were concerned about the study’s eligibility
criteria, which were informed by the intervention’s eligi-
bility conditions. At times, the discussion focused on
what was understood to be clinical uncertainty. This in-
cluded confusion about the middle ground between
patients who were being actively treated and those at the
end of life. There was evidence of disagreement between
professional groups about which patients were potential
cases. We observed a sentiment of a perceived disparity
of power between doctors and nurses concerning how
decisions were made about which patients could be
approached. At control site 1, the research nurse and
ward sister explained their difficulty with recruitment
because clinical uncertainty was not fully understood by
doctors as being a legitimate concept. Medical staff
raised serious concerns that they perceived prognostica-
tion was required to confirm a patient as at risk of dying
during their stay to meet the eligibility criteria. The con-
cept of at risk was problematic to implement as an ob-
jective criterion, with perceptions of subjectivity
surrounding risk and variation in interpretation of risk
within and across the clusters.
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Table 2 Baseline participant characteristics by trial arm
N (%) for whole sample, N = 65 N (%) for control, N = 36 N (%) for intervention, N = 29
Gender
Male 33 (50.8) 22 (61.1) 11 (37.9)
Female 32 (49.2) 14 (38.9) 18 (62.1)
Age
50–64 10 (15.4) 9 (25.0) 1 (3.5)
65–79 25 (38.5) 18 (50.0) 7 (24.1)
80+ 30 (46.2) 9 (25.0) 21 (72.4)
Mean (standard deviation) 77.8 (12.3) 71.8 (10.8) 85.3 (9.7)
Disease group
Cancer 30 (46.2) 23 (63.9) 7 (24.1)
Non-cancer 35 (53.8) 13 (36.1) 22 (75.9)
Patient had capacity
Yes 23 (35.4) 17 (47.2) 6 (20.7)
No 42 (64.6) 19 (52.8) 23 (79.3)
Education
Did not go to school 3 (4.6) 3 (8.3) 0
Secondary school (GCSE/O Level) 21 (32.3) 9 (25.0) 12 (41.3)
Secondary school (A Level) 15 (23.1) 6 (16.7) 9 (31.0)
Vocational qualification 4 (6.2) 2 (5.6) 2 (6.9)
University 11 (16.9) 7 (19.4) 4 (13.8)
Prefer not to say 7 (10.8) 6 (16.7) 1 (3.5)
Missing 4 (6.2) 3 (8.3) 1 (3.5)
Marital status
Single 10 (15.4) 6 (16.7) 4 (13.8)
Widowed 26 (40.0) 9 (25.0) 17 (58.6)
Married, civil partnership, or long-term relationship 27 (41.5) 19 (52.8) 8 (27.6)
Divorced 1 (1.5) 1 (2.8) 0
Missing 1 (1.5) 1 (2.8) 0
Ethnicity
White British 45 (69.2) 17 (47.2) 28 (96.6)
Other white 2 (3.1) 1 (2.8) 1 (3.5)
White or black African 1 (2.8) 1 (2.8) 0
White and Asian 1 (2.8) 1 (2.8) 0
Other mixed 1 (2.8) 1 (2.8) 0
Indian 7 (10.8) 7 (19.4) 0
Pakistani 1 (2.8) 1 (2.8) 0
Other Asian 4 (6.2) 4 (11.1) 0
Caribbean 1 (2.8) 1 (2.8) 0
Other black 1 (2.8) 1 (2.8) 0
Missing 1 (2.8) 1 (2.8) 0
Income
Living comfortably at present 26 (40.0) 14 (38.9) 12 (41.4)
Coping on present income 21 (32.3) 12 (33.3) 9 (31.0)
Difficult on present income 5 (7.7) 0 5 (17.2)
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There was also discussion about when an episode of
care could be considered to have ended. While this
was objectively on a patient’s discharge, there was a
strong sentiment that the recommendations of care
should be maintained from hospital to home or care
home. It was not within the scope of the study to in-
vestigate this.
Although we did not ask about study contamination at
the focus groups in the control sites, a small number of
participants stated that merely thinking about clinical
uncertainty, albeit in the absence of an intervention to
guide them, had influenced their clinical practice. Partic-
ipants mentioned that the study provided them with a
platform to broach difficult topics, such as clinical un-
certainty and advance care planning, with patients and
their families.
Consideration of study settings and processes
Views were shared about site-level factors external to
the study protocol and how they had a bearing on the
success of the study. The system of consultant oversight
of a ward was a critical factor to consider when setting
up the study. At one of the control sites, by the time a
consultant had become familiar with the study and its
requirements, they had been replaced by a new consult-
ant who needed to be introduced to the study.
Explaining the study to patients and families, with the
study documentation, was challenging for some as they
assumed that the primary focus was dying. This was not
the case, but these comments further highlight the de-
gree of specificity needed when training staff in study
processes and interpreting the intervention’s eligibility
conditions, which governed the study’s eligibility criteria.
Health professionals also reported that the consent
and consultee assent process was challenging, highlight-
ing the extensive length of the participant information
sheets and the manner in which consent was sought (as
required by the research ethics committee). They sug-
gested modifications to streamline this process.
The impact of the feasibility study on research nurses
The emotive and complex nature of the study was dis-
cussed. At one site, we hoped to have a larger team of
research nurses, given the need to screen patients daily.
However, only a few research nurses felt adequately
skilled to attend ward handover meetings to identify po-
tential patients and then lead potentially distressing
encounters with patients, many of whom were very un-
well. Other research nurses felt that the unique focus of
the study provided them with a privileged position and
opportunity to develop deeper relationships with the pa-
tient participants.
Discussion
This account of the design and execution of this feasibil-
ity cluster RCT of the AMBER care bundle provides
evidence of the important methodological issues that
arise in studies of interventions for patients nearing the
end of life. Whilst a full trial of the AMBER care bundle
is technically possible, it would not be realistic using the
methods employed. This feasibility cluster RCT study
was difficult to perform for a myriad of intervention-
Table 2 Baseline participant characteristics by trial arm (Continued)
N (%) for whole sample, N = 65 N (%) for control, N = 36 N (%) for intervention, N = 29
Very difficult on present income 2 (3.1) 2 (5.6) 0
Prefer not to say 2 (3.1) 0 2 (6.9)
Don’t know 6 (9.2) 5 (13.9) 1 (3.5)
Missing 3 (4.6) 3 (8.3) 0
Table 3 Number of morbidities by International Classification of Diseases, Revision 10 by study site, study arm, and total
Morbidity Control site 1
N = 8
Intervention site 1
N = 20
Intervention site 2
N = 9
Control site 2
N = 28
Control arm
N = 36
Intervention arm
N = 29
Total
N = 65
Neoplasms 7 2 1 17 24 3 27
Respiratory system 0 1 4 7 7 5 12
Mental disorders 1 11 1 3 4 12 16
Circulatory system 4 8 3 14 18 11 29
Musculoskeletal 0 4 2 4 4 6 10
Blood disorder/endocrine 4 2 1 11 15 3 18
Digestive system 3 2 0 3 6 2 8
Neurological 0 4 3 4 4 7 11
Other 0 1 2 1 1 3 4
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based, logistical, and methodological reasons. However,
it provides vital evidence to inform future research
evaluating complex interventions for patients nearing
the end of life in hospital settings.
The study has several important strengths. It was a
clinical trial of a complex hospital-based intervention,
recruiting 65 patient participants, many whom were eld-
erly and frail with multiple morbidities, achieving 81.3%
of our recruitment target, over an extended recruitment
period. Moreover, it collected data from these individ-
uals at multiple time points. The knowledge gained from
this study contributes to progressing how research can
be conducted with patients near the end of life [45, 46].
Patient participants viewed involvement in the study
positively and many were grateful for the opportunity to
share their views and experiences. This challenges com-
monly held misconceptions that research among this
patient population is unnecessarily intrusive [47]. Add-
itionally, we purposefully selected four hospitals, with
different specialties, serving different parts of the coun-
try, which enhances the generalisability of our findings.
Study eligibility criteria and recruitment
Referring clinicians and research nurses require that the
eligibility criteria for a clinical trial to be clear and un-
ambiguous. In the present study, the criteria created a
number of sampling challenges outlined below.
First, the AMBER care bundle eligibility conditions op-
erated as the eligibility criteria for the feasibility trial,
which referring clinicians and research nurses found
confusing. Beyond a patient being identified as deterior-
ating, clinically unstable with limited reversibility, pa-
tients were also required to be at risk of dying during
their current episode of care, despite treatment. The
combined evidence from the screening logs and the
views of health professionals in the focus groups
highlighted that the prognostic element of the criteria
was a major impediment when identifying and recruiting
potential patient participants. Whilst this finding was
germane to both trial arms, it was more pronounced in
the control arm due to lack of training and confidence
in identifying potential patients. Prognostic models vary
in levels of sophistication, ranging from clinical intuition
to more intricate multivariate statistical models that
combine multiple factors to yield an assessment [48]. If
risk of dying is to be retained as an eligibility criterion,
there is a continued risk of two sampling biases being
present due to the unknown (or the inconsistent) man-
ner in which health professionals currently interpret risk.
Firstly, there is the unpredictable and often unreliable
identification of potential participants within and across
study sites, and secondly their exclusion. The findings
from the health professional focus groups and analysis
of the recruitment logs suggest both biases were indeed
present. Although models to enhance the identification
of dying patients using prognostic models are improving
for patients with cancer [49–51], there is far less consen-
sus on methods to assess patients with non-malignant
Table 4 Number of morbidities by study site, study arm, and total
No of morbidities per patient Control site 1
N = 8
Intervention site 1
N = 20
Intervention site 2
N = 9
Control site 2
N = 28
Control arm
N = 36
Intervention arm
N = 29
Total
N = 65
Missing 0 1 1 0 0 2 2
1 1 9 3 7 8 12 20
2 3 5 2 11 14 7 21
3 4 4 2 5 9 6 15
4 0 1 1 5 5 2 7
Mean (standard deviation) 2.38 (0.74) 1.84 (0.96) 2.13 (1.13) 2.29 (1.05) 2.31 (0.98) 1.93 (1.00) 2.33 (1.09)
Table 5 Descriptive analysis of participant self-reported outcomes for participants who had data at baseline and 3–5 days, by study
arm
Primary outcome measures Baseline, mean (SD) 3–5 days, mean (SD) 10–15 days, mean (SD)
IPOS subscale 5 Control, N = 12 13.3 (4.8) 13.3 (3.9) 10.3 (1.2) 1
Intervention, N = 12 13.3 (5.1) 14.6 (4.1) 13.9 (5.3) 2
howRwe 6 Control, N = 8 13.1 (2.5) 13.9 (2.5) 14 (2.0) 3
Intervention, N = 2 11.5 (2.1) 12.0 (0) 11 (N/A)4
1N = 3
2N = 7
3N = 3
4N = 1
5 A higher score is worse for patients. For the subscale, seven items are scored 0–4. Possible scores range from 0 to 28
6 A higher score is better. Four items are scored 1–4. Possible scores range from 4 to 16
SD standard deviation
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Table 6 Health and social care utilisation and informal care provision for the past 3 months at the baseline interview
Control Intervention
N User Utilisation N User Utilisation
n % Mean s.d. n % Mean s.d.
Overnight stay
Intensive care unit 36 6 17.0 4.2 5.4 29 0 0.0 n/a n/a
Inpatient ward 36 22 61.0 10.8 10.2 29 15 52.0 22.3 25.9
Hospice 36 3 8.0 60.0 n/a 29 0 0.0 n/a n/a
Nursing home 36 2 6.0 3.0 n/a 29 1 3.0 76.0 n/a
Residential home 36 2 6.0 69.5 13.4 29 4 14.0 55.0 29.8
A&E 36 15 42.0 1.9 1.1 29 12 41.0 1.8 1.7
Emergency ambulance 36 15 42.0 1.9 1.3 29 13 45.0 1.5 0.7
Outpatient
Palliative care 36 4 11.0 2.0 0.8 29 1 3.0 1.0 n/a
Radiotherapy 36 7 19.0 2.0 1.2 29 0 0.0 n/a n/a
Oncology clinic 36 13 36.0 2.5 1.5 29 1 3.0 2.0 n/a
Other appointment 36 12 33.0 2.5 1.4 29 6 21.0 2.0 1.3
Hospital transport ambulance 36 2 6.0 12.5 16.3 29 4 14.0 7.3 5.6
GP face to face 36 28 78.0 2.7 1.6 29 25 86.0 3.4 2.6
GP on the phone 36 24 67.0 2.9 1.2 29 17 59.0 2.6 2.5
Nurse
Marie Curie 36 4 11.0 1.3 0.5 29 1 3.0 2.0 n/a
McMillan or palliative care 36 9 25.0 3.4 2.3 29 1 3.0 1.0 n/a
Other 36 4 11.0 1.5 0.7 29 3 10.0 1.0 0.0
Palliative care or hospice at home team 36 7 19.0 3.0 2.6 29 0 0.0 n/a n/a
Physiotherapist 36 8 22.0 2.4 0.9 29 7 24.0 2.5 1.9
Occupational therapist 36 6 17.0 2.0 1.1 29 6 21.0 2.4 1.5
Psychiatrist 36 0 0.0 n/a n/a 29 0 0.0 n/a n/a
Psychologist or counsellor 36 3 8.0 1.7 1.2 29 0 0.0 n/a n/a
Spiritual care person 36 0 0.0 n/a n/a 29 3 10.0 6.3 3.8
Social worker 36 5 14.0 3.5 4.4 29 0 0.0 n/a n/a
Paid formal carer 36 4 11.0 90.0 0.0 29 13 45.0 20.7 24.0
Dietician 36 9 25.0 1.8 0.7 29 4 14.0 3.0 2.6
Voluntary service 36 1 3.0 0.0 n/a 29 0 0.0 n/a n/a
Other professionals 36 4 11.0 1.0 0.0 29 2 7.0 35.5 48.8
Investigation or diagnostic tests
Blood test 36 35 97.0 13.8 8.7 29 18 62.0 5.6 6.5
X-ray 36 28 78.0 3.3 3.8 29 13 45.0 2.7 1.1
Echocardiogram 36 9 25.0 1.5 0.5 29 5 17.0 1.0 0.0
Electrocardiogram 36 20 56.0 1.9 1.0 29 10 34.0 1.2 0.4
Ultrasound 36 17 47.0 1.5 0.8 29 3 10.0 1.5 0.7
Computed tomography scan 36 27 75.0 1.8 1.0 29 7 24.0 1.2 0.4
Magnetic resonance image 36 13 36.0 1.6 0.9 29 1 3.0 2.0 n/a
Other 36 17 47.0 4.3 6.0 29 7 24.0 1.2 0.4
Informal care (hours)
Personal care 36 20 56.0 30.9 44.8 29 15 52.0 16.3 29.6
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conditions, which are more common in studies of this
nature [52, 53]. If similar complex interventions are to
be evaluated, the subjectivity in prognostication must be
avoided and greater emphasis placed on objective clin-
ical indicators, for example, poor performance status
scores, the presence and severity of cognitive impair-
ment, weight loss, and dysphagia.
Second, equipped with the participant information
sheets, clinicians were required to introduce the study to
potential patient participants and its relevance to them
in relation to their clinical situation. Some clinicians, es-
pecially at the control sites, reported they lacked the
confidence and skills to talk openly with patients about
their circumstances. This challenge was exacerbated by
research nurses’ reports that while convinced that some
patients identified were ideal for the study, their views
were challenged by clinical colleagues who disagreed on
their suitability, stating that they were unclear that they
were at risk of dying during the admission. This inad-
vertent gatekeeping represented an important barrier to
recruitment. In the clinical care of people approaching
the end of life, patients value their autonomy in
decision-making. This also applies to research participa-
tion, where the opportunity to help others, and to be
heard, must be respected [54]. Preventing this, whether
intentionally or unintentionally, may violate the ethical
principle of fairness [55]. Future studies should test
methods that train health professionals in conducting
difficult conversations about introducing studies of this
nature to potential patient participants, whilst being
mindful that this training does not contaminate the
study by corresponding too closely to the intervention to
be tested.
Third, it was challenging to ensure homogeneity in
how patients were identified at and across sites. Fre-
quent staff turnover (notable at one site) may lead to
inconsistencies (and potentially, bias) in the way poten-
tial patients are identified and recruited. It proved chal-
lenging for the research site’s principal investigators and
researchers to identify whether the criteria were system-
atically applied and to track reasons for non-
participation. Such tracking is invaluable, alerting
Table 6 Health and social care utilisation and informal care provision for the past 3 months at the baseline interview (Continued)
Control Intervention
N User Utilisation N User Utilisation
n % Mean s.d. n % Mean s.d.
Help with medical procedures 36 18 50.0 8.4 5.6 29 12 41.0 5.5 9.2
Help inside the home 36 24 67.0 6.6 4.3 29 17 59.0 6.5 4.2
Help outside the home 36 25 69.0 8.3 6.9 29 17 59.0 2.3 1.4
Time spent on call 36 13 36.0 26.5 51.7 29 11 38.0 48.2 68.6
Other 36 4 11.0 4.7 2.5 29 4 14.0 7.3 9.5
EQ-5D index score 33 – – 0.00 0.33 28 – – −0.08 0.14
A&E accident and emergency department, GP general practitioner, n/a not applicable. s.d. standard deviation
Table 7 Characteristics of health professionals attending focus groups by study site
Site Intervention site 1
(N = 11)
Intervention site 2
(N = 15)
Control site 1
(N = 9)
Control site 2
(N = 11)
Specialties Geriatrics Respiratory Haematology
Diabetes
Rheumatology
Endocrinology
Job titles
(gender)
Consultant geriatrician, ward
X (F)
Consultant geriatrician, ward
Y (M)
Ward clerk, ward Y (F)
Ward sister, ward Y (F)
Ward manager (F)
Ward manager assistant (F)
Physician associate, ward X
(F)
Matron, ward X (M)
Nurse assistant (M)
Research nurse (F)
Research nurse (F)
Junior ward sister (F)
Staff nurse (F)
Registrar (F)
Senior house office (F)
Foundation Year 1 Doctor (F)
Senior house office (F)
Junior doctor (M)
Matron (F)
Palliative care clinical nurse
specialist (F)
Research nurse (F)
Ward manager (F)
Junior doctor (M)
Senior house office (F)
Registrar (M)
Foundation Year 1 Doctor (M)
Locum senior house officer
(M)
Band 5 occupational
therapist (F)
Ward sister (F)
Research nurse (F)
Research practitioner (F)
Matron of research (F)
Staff nurse (F)
Palliative care consultant (M)
Senior house officer (F)
Consultant rheumatologist (M)
Consultant endocrinologist (F)
Physiotherapy technician (F)
Research coordinator (F)
Rheumatology senior house
officer (F)
GP senior house officer (F)
Foundation Year 1 Doctor (M)
Registrar rheumatologist (M)
Foundation Year 1 Doctor (F)
Duration 50 minutes 49 minutes 60 minutes 65 minutes
F female, M male
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Table 8 Themes and illustrative quotes from focus groups with health professionals
Issues Illustrative quotes
Concerns relating to study eligibility criteria
Subtleties in relation to the study
eligibility criteria
It’s quite subjective, but that’s probably good. If you put strict criteria, you might miss some.
Like we were saying, it’s almost like a feeling isn’t it, that’s someone is uncertain. It’s not this
metric thing. You know, otherwise like this is a marker of uncertainty. I quite like the fact that
the criteria are … just that, uncertain. Int1013-M-CONS
My reflection is I think it’s just a bad expression [the eligibility criteria]. It’s the question of defining
what the ‘episode of care’ is. It’s really what’s it came down to, wasn’t it? Initially, I was told that
the episode of care finishes as the patient leaves the backdoor, which really isn’t true, is it? That’s
the whole point of whoever is following their care to the community, as far as a patient is
concerned. I’m hoping their perception of an episode of care isn’t ‘The back door is closed,
you’re in the ambulance going home and that’s it.’ Con2020-M-CONS
Professional discordance and the
eligibility criteria
I think that’s been particularly difficult in this study. I think that is why we struggled to recruit.
Because what we perceived to be a patient wasn’t certain (i.e. uncertain), and this was not
the view of the medical team. I think it’s either ‘We are actively treating’ or ‘End of life’
[approving hhhmms in the background from the other research nurses]. You know there’s
no ‘in-between’. Con1021-F-RN
The medics would say ‘No, they’re not’ [about patients identified as fulfilling study eligibility
criteria]. But just listening to the handovers, it was like you’d identify everybody in the ward.
Con1018-F-WS
It came to a point where we [the research nurses] had explained it [the study] and explained
it again. I think it got to a point where they [the clinicians] just said: ‘No, no, they’re not eligible.’
Con1021-F-RN
Issues with the prognostication of
dying
My worry is ‘the risk of death’ can be differently interpreted. So, I think being a bit more concrete
about the ‘risk of death’ would be good. Con2020-M-CONS
Well, sometimes it’s hard predicting whether they’ll die during this admission or when they’re going
home … They might not die in this admission, but they are at the end of life in the next few months.
Int2019-F-SHO
Contamination of usual care I’ve learned a lot from being involved in the ImproveCare study. I think it made it much more comfortable
for me to go for these discussions. I think when I was earlier, pretty early in my training days, it was very
difficult, when we got asked all these different questions, probably I didn’t have answers for and they kept
asking why can’t we do this, why can’t we do that and I didn’t understand but then when you get a better
understanding of it, if you’re comfortable in touching these subjects. Con2019-M-REG
Study setting and study processes
Consultant oversight of study ward The consultant changes every week and there’s there are five or six of them, aren’t there? So, they’re there
every fifth week and you know, you happen to tell them every week about the study, remind them that
the study is going on. Con1023-M-CONS
Misinterpreting clinicians’ explanations
of the study
The daughter of the patient told me I was ‘Dr Death’ and ‘the Grim Ripper’! They were very upset about it
and I think it was largely because they didn’t understand. Con2020-M-CONS
Process of seeking consent You give the four-sided A4 booklet PIS [participant information sheet] to an 80 year old. It knackers them out.
They say read it to me. I get halfway through and they’re falling asleep because they are so, so, sick.
Int2003-F-RN
The consent process also needs to be changed. There is nothing to say, you have to get a ‘written consent’ and
I think you need to be pushing these boundaries with the ethics committees. This is why research in this specialty
is not being done. You would’ve had dozens of more questionnaires completed, dozens. Why can’t when I go in to
a see a patient ask: ‘Mr Smith would you mind answering some questions about your condition and how we’ve
been treating you?’ ‘Yes, no problem.’ ‘Okay. Mr Smith, you do understand that you don’t have to do this?’ ‘Yes’
‘You do understand that you can stop at any time.’ ‘Yes.’ So, I can tick those and start asking questions. You
would’ve had an 80% completion rate! Int2003-F-RN
Challenges of recruiting patients who
lacked mental capacity
The actual recruitment process was sometimes quite difficult because of what you said, the families not being
here. Most of the patients we approached, we had to contact the relatives because the patients were too unwell.
So being able to liaise with the families was difficult. We can’t be waiting for the families here, so we were called
back about relatives that were here and popping back and asking the ward staff to tell us when they’re here. So,
the practicalities were difficult. Int1033-F-RN
Views on being involved in the feasibility study
Mixed views on involvement in
study recruitment
It was just two members of staff who came up every day, looking. A lot of the other staff felt so uncomfortable
working in this area, if we’re honest. The two who did do it, in the end, found all the end-of-life stuff really tiring,
even though wasn’t strictly an ‘end-of-life’ care study. The fact is that we got a paediatric nurse and a stroke nurse,
and they felt a bit out of their depth. Con1020-F-RP
For the patients, I don’t think there was negative impact. … However, I don’t think the staff on the ward were
keen. Con1021-F-RN
I was really, really impressed about how on-board everybody was and everybody knew what AMBER was. On the
whole, generally 90% of the time people were very supportive of our presence and what we needed to do.
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researchers to the need to amend recruitment ap-
proaches before the study progresses too far and a vital
pool of potentially eligible patients are inadvertently ex-
cluded. Related to this, accurate reporting of the number
and characteristics of patient participants successfully re-
cruited, and data on non-participants, greatly assists in
the identification of possible sample bias that may com-
promise a study’s validity [56, 57]. We adopted the
CONSORT and Transparent Reporting of Evaluations
framework [58], aiming to report clearly and transpar-
ently the selection of the study sample in relation to the
study’s eligibility criteria, the characteristics of partici-
pants and non-participants, and refusals. However, only
one study site provided a detailed screening log that
adequately met this requirement. Without this informa-
tion, not only is it more challenging to identify and
correct instances of misinterpretation of study eligibility
criteria and to manage potential gatekeeping, but it also
prevents the wider research community from under-
standing potential threats to the internal validity of stud-
ies examining similar issues. During the planning stage
of a study, researchers need to be transparent about the
resources required for the screening process and require
study sites to record screening information. Since there
is currently no agreed ethical standard for recording
non-identifiable information within screening logs [59],
training research staff, or delegated individuals, at each
study site to collect minimum patient-based data may be
helpful.
Study involvement procedures
A number of important findings are evident from the
process of seeking informed consent from patient partic-
ipants. The participation information sheets and consent
sheets were developed in concert with our patient and
public involvement members and subsequently approved
to the satisfaction of the research ethics committee and
the UK Health Research Authority. However, we discov-
ered they were not always well suited to their intended
audience: those who were older, often frail, and very un-
well. The research nurses highlighted that the documen-
tation was lengthy, too detailed, and complex, a result of
the need to include information and contingencies for
those patient participants who might lose capacity
during the study. Thus, some potential patient partici-
pants were discouraged from enrolling in the study.
Whilst research has focused on the ethical requirements
of dementia-related research, where important lessons
can be learned [60], little guidance currently exists for
developing study documentation for end-of-life care
studies that are adequately detailed to satisfy potential
participants and research ethics committees alike [61].
Future studies in this area should consider using a
briefer version of the participant information sheet when
first approaching potential patient participants. If they
display interest in the study, then the full version of the
participant information sheet could be provided to them
that includes information on transparency in accord
with the recently introduced General Data Protection
Regulation and information on the legal basis for data-
processing.
Related to this, the process of recording informed
consent also requires consideration. According to the
Council for International Organizations of Medical
Sciences and the World Health Organization, it is per-
missible for researchers and research ethics committees
to consider modifying consent procedures as long as
they preserve as much of the informed consent process
as possible to enable participants to understand the gen-
eral nature of a study and to make a meaningful in-
formed decision whether to participate [62]. The criteria
for considering changes include: (i) the research would
not be feasible or practicable to carry out without modi-
fication, (ii) the research has important social value, and
(iii) the research poses no more than minimal risks to
participants. We believe studies like ours should be per-
mitted to test alternative methods of obtaining consent
to evaluate their acceptability and utility from the per-
spectives of potential participants.
Contamination of the control group
When designing this feasibility study, we deliberately
made use of a cluster design to minimise the potential of
study contamination [26, 27, 63] associated with the
movement of health professionals acquainted with the
AMBER care bundle to a control ward, which may influ-
ence the care given to patients. This represented an im-
provement in the design from our previous comparative
Table 8 Themes and illustrative quotes from focus groups with health professionals (Continued)
Issues Illustrative quotes
Int1033-F-RN
Greater insight into patients’
experiences
(The study) gave us a unique relationship with the relatives. So, in a strange way, you're in a unique position that
they talk to you about things that sometimes they feel that they can't take forward with certain ward staff. So,
we are able to encourage them into having those conversations making sure that those communications
were taking place with ward staff if they, the family had some anxiety or a certain query. So, whether because
we were seen as external or whether we would able to form a relationship over questionnaires being done
different points, I just don't know. Int1033-F-RN
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evaluation of the AMBER care bundle [34]. We were
also mindful not to select study sites where similar inter-
ventions were in place. This is because changes to the
standard or usual care during a clinical trial could impair
the validity of the study. Although control site 1 did ex-
perience a relatively frequent turnover of medical staff,
to the best of our knowledge no health professionals
were familiar with the AMBER care bundle from having
worked elsewhere. However, at control site 2, we be-
come aware of a change in clinical practice associated
with subtleties in maturation, or naturally occurring
changes [64] in health professionals’ clinical practice
resulting from them becoming more familiar with the
concept of clinical uncertainty, which was not accom-
panied by any formal training of an intervention for pa-
tient and family care. Due to the small number of
participating patients in both arms of the study, it was
not possible to quantify the effect of this change
accurately.
Data collection and completeness of candidate primary
outcome measures
We examined whether relevant clinical outcomes can be
measured using instruments that could be easily com-
pleted by unwell patients whose recovery is clinically un-
certain [65]. All participants (n = 65) who provided
consent or proxy assent successfully completed the base-
line measures. Overall, the levels of missing data for self-
reported outcomes and those provided by proxies were
very low for both candidate primary outcome measures.
However, the howRwe is a patient-completed experience
measure so that it cannot be used for those who lack ad-
equate mental capacity. This severely restricted the
number of participants who were able to complete this
measure. Nevertheless, the findings indicate that data
collection was generally possible. We also now believe
that utilising health resources for the follow-up could be
replaced by accessing patients’ medical records, assum-
ing all the patients stay on wards. The costs associated
with care service use would then be obtained using unit
costs for each service item and opportunity costs (e.g. a
minimum wage).
Acceptability of the study to patient participants
We have demonstrated that patient participants were
generally very positive about being involved in this feasi-
bility study. This continued for all those who remained
in the trial until the second follow-up at 10–15 days.
Within this study, we have refuted legitimate concerns
about engaging with what could be perceived as vulner-
able patient populations at the end of life [66–68]. This
study, therefore, demonstrates that when ethical and
pragmatic decisions are made in relation to study design,
combined with highly sensitised research nurses and re-
searchers, the voice of patients can be heard.
Study limitations
There are a number of study limitations associated with
this feasibility study beyond those already discussed.
First, guided by the AMBER care bundle development
team, we used heat maps to identify wards with the
highest number of annual patient deaths. Consequently,
we did not include wards with similar specialties across
the trial arms. This resulted in a case mix of patients
that was quite different between the arms. The effect of
this was most pronounced with the inclusion of care-of-
the-elderly wards, which skewed the age balance across
the trial arms. The mean age of the participants in the
intervention arm was higher than that in the control
arm. Future studies should not base the selection of
study wards solely on the number of deaths per ward,
and should consider other important factors, for ex-
ample, ward specialty, the potential for active engage-
ment of ward staff, and the presence of principal
investigators on the ward.
Second, we are mindful that this study represented a
feasibility study with no requirement for a formal power
calculation since effectiveness was not being evaluated.
Based on available data of deaths on wards, or within
100 days of discharge, we estimated that over the period
of the feasibility study, we would be able to recruit 40–
45 patients in each arm. However, we recruited 65. This
reduced number of patient participants has some impli-
cations for fulfilling the key objectives of the feasibility
study, specifically, understanding how best to recruit,
examining study participant retention, testing data col-
lection tools for the trial and determining what would be
their optimum timing in a larger trial, and examining
the acceptability of the overall trial. Additionally, the
relatively small number of clusters included in the study
meant that we were not able to calculate the intra-
cluster correlation coefficient required for a future trial.
Feasibility studies adopting this trial design should con-
sider extending the number of clusters.
Third, the main reason for the loss to follow-up was
due to participants being discharged from the study
wards, which was evident in both arms of the study.
Since we collected data from participants only when they
were on the study wards, we were not able to continue
data collection after their discharge. Future similar stud-
ies should consider a design that either aims to recruit
patients at an earlier point in their hospital admission or
permits follow-up after discharge. A potentially more ap-
propriate commencement point for recruitment within a
hospital could be when patients are in an acute medical
unit. Decisions regarding patients’ further treatment and
care within a hospital often take place in the acute
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medical unit, and there is often clinical uncertainty at
this time. This would allow data to be collected for a lar-
ger number of patient participants at the third time
point (10–15 days), who would otherwise have been
discharged.
Conclusions
In recent years the number of feasibility trials conducted
in palliative care has increased and they have become an
important requirement for funding bodies as well as be-
ing of high value to researchers in justifying study
designs (to both funders and ethics committees). How-
ever, noticeably absent from many feasibility studies
reported are those that conform to the recommendation
that clear feasibility objectives are in place beforehand to
inform whether the study protocol is ultimately feasible
[22, 69]. This feasibility study conformed to this recom-
mendation and concluded that whilst the study was
indeed technically possible, based on the challenges re-
ported and the number of design modifications required,
it would be impractical to use the protocol tested to
guide a full trial of the AMBER care bundle. This study
has, therefore, accomplished an important positive ob-
jective of a feasibility trial [25]: the de-risking of funding
of a full clinical trial estimated to cost £1.2 million that
would be unlikely to meet the necessary patient recruit-
ment and retention rates necessary to identify a clinically
meaningful outcome. Meanwhile, however, the AMBER
care bundle continues to be used extensively in many
hospitals and endorsed in policy [70].
We suggest that future studies attempting to conduct
research among this patient population, and importantly
the complex interventions designed to benefit them,
should consider the following four recommendations:
1. Effective timely participant recruitment is essential,
since it has a significant impact on findings. Health
professionals and research nurses involved in
studies of this nature, therefore, require specific
training to give them the right skills and to make
them feel confident in identifying and then
recruiting potential patient participants. Some may
feel hesitant and on occasion upset, given the focus
of the study. Training should, therefore, be
accompanied by regular debriefings that openly
discuss instances of study-invoked distress.
2. Palliative populations are heterogeneous and have a
range of disease trajectories [71]. Study populations
should, therefore, reflect the real world and be
feasible to study. This may, therefore, require broad
[72] rather than overly specific eligibility criteria.
3. Make use of population-based retrospective
hospital-based data to examine and compare pa-
tients supported by an intervention with those in a
control group, adjusted for propensity matching.
Similar approaches have been successfully employed
to examine the quality of care received by cancer
patients [73]. Areas of care would have to be speci-
fied for patients who died during their hospital stay
or within 100 days of discharge, and importantly for
those who survived, a central feature of the AMBER
care bundle. Domains of interest might include
informing family members when death was
imminent, the use of validated tools to assess com-
mon symptoms (e.g. pain), prescribing drugs for
anxiety, the use of bereavement support when avail-
able, length of hospital stay, preferred and actual
place of death, number of hospital readmissions,
and admissions to emergency departments.
4. Feasibility studies that examine methods to research
complex interventions focused on clinical
uncertainty and at the end of life are vital for
improving the design of future trials, giving them a
greater chance of being completed successfully, on
time, and with the required sample size [63, 74, 75].
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